DDInter1676 DDInter714
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pralsetinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Fedratinib may lead to a major life threatening interaction when taken with Tamoxifen
Fedratinib may lead to a major life threatening interaction when taken with Lurbinectedin